<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944307</url>
  </required_header>
  <id_info>
    <org_study_id>09-0475</org_study_id>
    <nct_id>NCT00944307</nct_id>
  </id_info>
  <brief_title>Effect of Antacids on the Pharmacokinetics of Raltegravir</brief_title>
  <official_title>Effect of Antacids on the Pharmacokinetics of Raltegravir in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether there is a drug interaction between raltegravir&#xD;
      (a medicine used to treat the human immunodeficiency virus or HIV) and antacids.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will determine if an interaction occurs between the HIV medicine raltegravir and&#xD;
      an antacid. A prior study found an interaction with another medicine like raltegravir called&#xD;
      elvitegravir and an antacid. The elvitegravir levels were reduced by half. The same&#xD;
      interaction may occur with raltegravir and an antacid based on the structure of this medicine&#xD;
      and how it works. When the levels of HIV medications are reduced, people with HIV can &quot;fail&quot;&#xD;
      their treatment. The virus can multiply when the drug levels are too low and the medications&#xD;
      can stop working. We need to be sure that antacids will not cause this problem with&#xD;
      raltegravir.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Raltegravir AUC with and without an antacid</measure>
    <time_frame>0-48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Raltegravir Cmax with and without an antacid</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>raltegravir alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a single dose of 400 mg raltegravir orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>raltegravir plus antacid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of 400mg raltegravir orally simultaneously with an antacid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>raltegravir 400mg orally once</description>
    <arm_group_label>raltegravir alone</arm_group_label>
    <arm_group_label>raltegravir plus antacid</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antacid</intervention_name>
    <description>aluminum, magnesium, simethicone-containing antacid 30mL orally once</description>
    <arm_group_label>raltegravir plus antacid</arm_group_label>
    <other_name>Isentress, Maalox Plus Extra Strength</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Absence of HIV-1 infection as documented by any licensed ELISA test kit within 21 days&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Age greater than or equal to 18 but less than or equal to 60 years.&#xD;
&#xD;
          -  Ability and willingness to give written informed consent.&#xD;
&#xD;
          -  Within 30% (+/-) of ideal body weight and total body weight of â‰¥ 50 kg.&#xD;
&#xD;
          -  Hematology, Metabolic Profile, Renal, and Hepatic Function tests all within normal&#xD;
             limits.&#xD;
&#xD;
          -  Creatine kinase (CK) less than 3 times the upper limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast-feeding.&#xD;
&#xD;
          -  Women and men of reproductive potential who are actively engaging in sexual activity&#xD;
             or assisted reproductive technology with the intent of pregnancy.&#xD;
&#xD;
          -  Allergy/sensitivity to raltegravir.&#xD;
&#xD;
          -  Allergy/sensitivity to antacids.&#xD;
&#xD;
          -  Active drug or alcohol abuse or dependence that, in the opinion of the investigator,&#xD;
             would interfere with adherence to study requirements. While on study, subjects will be&#xD;
             instructed not to consume alcohol for 48 hours prior the screening visit, and for the&#xD;
             24 hours preceding the intensive pharmacokinetic (PK) study visits and for 24 hours&#xD;
             following the completion of the study visits.&#xD;
&#xD;
          -  Any medical condition that, in the opinion of the investigator, would interfere with&#xD;
             the subject's ability to participate in this protocol.&#xD;
&#xD;
          -  Participation in any investigational drug studies within 30 days prior to study entry.&#xD;
&#xD;
          -  History of or active cardiovascular, renal, hematologic, hepatic, neurologic,&#xD;
             gastrointestinal, psychiatric, endocrine, or immunologic disease(s). This is inclusive&#xD;
             of chronic illnesses such as hypertension, coronary artery disease, arthritis,&#xD;
             diabetes, any chronic gastrointestinal conditions that might interfere with drug&#xD;
             absorption.&#xD;
&#xD;
          -  Use of investigational, prescription, and over-the-counter medications within 14 days&#xD;
             of study entry with the following exceptions: aspirin, acetaminophen, ibuprofen, and&#xD;
             oral contraceptives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer J Kiser, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>July 20, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>antiretroviral</keyword>
  <keyword>drug interaction</keyword>
  <keyword>human immunodeficiency virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Antacids</mesh_term>
    <mesh_term>Aluminum hydroxide, magnesium hydroxide, simethicone drug combination</mesh_term>
    <mesh_term>TEMPO</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

